uploads/2018/03/Chart-008-2-1.jpg

How AstraZeneca’s Other Products Portfolio Performed in 4Q17

By

Updated

Other products segment

AstraZeneca’s (AZN) other products include various neuroscience drugs, gastrointestinal drugs, and drugs for infections. The other products portfolio reported revenues of ~$1.1 billion during 4Q17, a 17% decline in operating revenues. The decline in revenues was due to lower sales of drugs like Nexium, Synagis, Seroquel XR, FluMist, and other products, partially offset by strong sales of Losec/Prilosec and Movantik.

Article continues below advertisement

Losec

Losec reported revenues of $69 million during 4Q17, a 14% increase in operating revenues as compared to 4Q16. The growth was driven by strong sales of Losec/Prilosec in the European markets and emerging markets, partially offset by lower sales of Losec in the US and established rest of the world markets during 4Q17.

Movantik

Movantik reported revenues of $30 million during 4Q17, a 15% increase in operating revenues as compared to 4Q16. The growth was driven by strong sales of Movantik/Moventig in the US and European markets during 4Q17.

Article continues below advertisement

Nexium

Nexium reported revenues of $427 million during 4Q17, a 12% decline in operating revenues as compared to 4Q16. The decline was due to lower sales of Nexium in the US and Established Rest of the World markets, partially offset by strong sales in emerging markets and European markets.

The US markets reported Nexium sales of $57 million, established rest of the world markets reported Nexium sales of $130 million, European markets reported Nexium sales of $72 million, and emerging markets reported Nexium sales of $168 million during 4Q17.

Synagis

Synagis reported revenues of $234 million during 4Q17, a 23% decline in operating revenues as compared to 4Q16. The decline in Synagis sales was due to lower sales of the drug in US and European markets during 4Q17.

Notably, the BLDRS Europe Select ADR ETF (ADRU) holds 20.9% of its total investments in healthcare companies. ADRU holds 2.5% in AstraZeneca ADR (AZN), 2.6% in GlaxoSmithKline ADR (GSK), 2.7% in Novo Nordisk ADR (NVO), and 6.2% in Novartis AG ADR (NVS).

Advertisement

More From Market Realist